Hematology/Oncology

Top Story

VIDEO: ASH recognizes research on molecular mechanisms of blood coagulation

December 12, 2019
Meeting News

Doptelet cost-effective, avoids transfusions for CLD-related thrombocytopenia

December 12, 2019
Treatment with Doptelet was cost-effective for the treatment of thrombocytopenia in patients with chronic liver diseases compared with other treatment options, according…
Drug Pipeline

Kite submits BLA to FDA for CAR T-cell therapy in mantle cell lymphoma

December 12, 2019
Biopharma company Kite, a subsidiary of Gilead, has submitted a biologics license application to the FDA for the company’s investigational chimeric antigen…
In the Journals

Associations urge caution after controversial radioactive iodine findings

December 12, 2019
The Society for Endocrinology and the British Thyroid Association issued a joint statement urging caution when interpreting a recent study linking radioactive iodine…
Meeting News

Anti-PD-1 therapy after CAR T-cell therapy shows efficacy in Hodgkin lymphoma

December 12, 2019
ORLANDO — Researchers demonstrated the clinical efficacy of anti-PD-1 mAb therapy following treatment with chimeric receptor modified T cells targeting the CD30…
More Headlines »
CME

Acute Lymphoblastic Leukemia Posters and Abstracts from San Diego

This activity is supported by educational funding provided by Amgen.

In this CME activity Elias Jabbour, MD, provides his perspectives on key posters presented at the American Society of…
More »
Video
Meeting News

VIDEO: Blinatumomab has potential to become ‘new standard of care’ as post-reinduction therapy for pediatric B-ALL

December 10, 2019
More »
Resource Centers
European Society for Medical Oncology Congress

European Society for Medical Oncology Congress

CME

2019 Texas Oncology Clinical Educational Symposium

This activity is supported by educational grants from AbbVie, Inc.; Celgene Corporation; Novartis Pharmaceuticals Corporation; Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc.; Takeda Oncology; and Verastem, Inc..

Clinical outcomes for advanced cancers continue to improve through the identification as well as the development of…
More »
Current Issues
View the Current Issue
HemOnc Today Cell Therapy Next